Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: All Mtn Ski who wrote (647)	11/9/1999 9:18:00 PM
From: lazarre	Respond to of 10345

I almost exclusively invest in INUT related stocks but realized that I needed to placate the conservative side of my brain which has been screaming for diversification for months. So I bought Elan 2 weeks ago or so at more or less where its at now. I chose ELAN for a couple of reasons but the biggie was a purely speculative one; its quest for a treatment for Alzheimers. I think that the fear of acquiring Alzheimers has surpassed most Americans' fear of coming down with cancer. At least with most cancers you have a fighting chance; not so with A. If ELAN is even moderately successful at allaying (sp?) the progression of A or even forstalling it, I think we all can divine the outcome. In any event, its a buy and hold. L

To: All Mtn Ski who wrote (647)	11/9/1999 10:47:00 PM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

11/8/99 Bus. Wire 09:22:00 Business Wire Copyright (c) 1999, Business Wire Monday, November 8, 1999 Endorex/Elan Oral Vaccine Delivery Joint Venture Receives New Patent CHICAGO--(BW HealthWire)--Nov. 8, 1999--Endorex Corporation (AMEX:DOR) announced today that its oral vaccine delivery joint venture with Elan Corporation, plc. (NYSE:ELN), had received notification from the U.S. Patent Office of the issuance of U.S. Patent No. 5,942,252 "Method for Delivering Bioactive Agents into and through the Mucosally-Associated Lymphoid Tissues and Controlling Their Release." The new patent describes methods for administering vaccine antigens, drugs, and other bioactive agents through mucosal tissues using biocompatible polymer microcapsules. The patent is one of a series of patents that the Endorex/Elan joint venture acquired earlier this year. The worldwide exclusive rights for the patent and the underlying technologies for the oral delivery of vaccines are licensed from the Southern Research Institute ("SRI") and the University of Alabama at Birmingham Research Foundation ("UABRF"). The new patent is the sixth U.S. patent that has been issued on the underlying microsphere encapsulation technology originating at UABRF and SRI and adds to a portfolio of more than 45 international patents covering various aspects of innovative drug delivery technology. The issued claims describe the uses of microcapsules, which can encapsulate vaccine antigens, in size ranges that permit transport and uptake of the microcapsules by immune-sensitive tissue in the intestine and by other mucosal surfaces. "The issuance of this new SRI/UABRF patent further expands the joint venture's extensive oral vaccine delivery intellectual property, and allows us to have a strong patent position in the area of delivery of vaccines," said Michael S. Rosen, Chairman and President of the joint venture and Endorex President/CEO. The joint venture was formed by Endorex and Elan in January 1998 to develop new oral and mucosal delivery systems for delivery of human and veterinary vaccines, a $6 billion market. The joint venture is developing several microencapsulation technologies applicable to oral and mucosal administration of new and current vaccines. Endorex Corporation is a drug delivery company. The Company's proprietary delivery technology, the Orasome(TM) system, was licensed from the Massachusetts Institute of Technology and is being developed for the oral and mucosal delivery of vaccines, proteins and peptides. Endorex has two joint ventures with Elan Corporation, plc, to develop novel delivery systems. Endorex is also focusing on two innovative directions in cancer therapy: natural chemotherapy and immunotherapy. Two Endorex cancer drugs have entered into multiple Phase II clinical trials: Perillyl alcohol, a new monoterpene, and ImmTher(R), an immunomodulator. The statements made in this press release contain certain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of known and unknown risks and uncertainties. Such statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, no assurance can be given that any of the Phase II clinical trials will show suitable efficacy or reflect positive indications from Phase I trials, the Company will initiate additional clinical trials or that such trials will be successful, or that any of the Company's cancer drug candidates will receive regulatory approval or become commercially successful, or that our issued patents will provide us with any competitive advantage, or that our patents will not be successfully challenged or circumvented by others. In addition to the matters described in this press release, risk factors as described from time to time in Endorex's filings with the Securities and Exchange Commission, including but not limited to its most recent reports on Form 10-QSB and Form 10-KSB, may affect the results achieved by Endorex. The Company assumes no obligation to update the information in this release. CONTACT: Endorex Corporation Michael Rosen, 847/573- 8990 mrosen@endorex.com or The Investor Relations Group Dian Griesel, Ph.D., 212/736-2650 or Jacqueline Resto, 212/736-2650 TheProTeam@aol.com 09:06 EST NOVEMBER 8, 1999 ---- INDEX REFERENCES ---- COMPANY (TICKER): DOR (DOR) NEWS SUBJECT: Business Wire; Press Release Wires (BW PREL)